Management of chronic hepatitis B in pregnancy

Clinics in Liver Disease

Volumn 14, Issue 3, 2010, Pages 495-504

  Buchanan, Corinne ^a   Tran, Tram T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HBsAg; Hepatitis B virus; Immunoprophylaxis; Pregnancy

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT HEPATITIS B VACCINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; HEPATITIS B VACCINE; IMMUNOGLOBULIN;

BIRTH DEFECT; BREAST FEEDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY LIVER; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LACTIC ACIDOSIS; NONHUMAN; PREGNANCY; PREGNANT WOMAN; PUERPERIUM; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; VIRUS LOAD; VIRUS TRANSMISSION; DRUG EFFECTS; FEMALE; HEPATITIS B VIRUS; IMMUNOLOGY; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; VERTICAL TRANSMISSION; VIROLOGY;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 77954642729     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.05.008     Document Type: Review

References (48)

1. Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Dis 2007, 11(4):945-963.
2. Alter M.J. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003, 39(Suppl 1):S64-S69.
3. Tran T. Hepatitis B and pregnancy. Curr Hepat Rep 2009, 8(4):154-156.
4. Jonas M. Hepatitis B and pregnancy: an underestimated issue. Liver Int 2009, 29(Suppl 1):133-139.
5. Gupta I., Ratho R.K. Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy. J Obstet Gynaecol Res 2003, 29(2):84-86.
6. Tran T.T., Keeffe E.B. Management of the pregnant hepatitis B patient. Curr Hepat Rep 2008, 2:43-48.
7. World Health Organization Hepatitis B World Health Organization fact sheet 204. Available at:, Accessed November 2009. http://who.int/inf-fs/en/fact204.html.
8. Centers for Disease Control and Prevention Implementation of newborn hepatitis B vaccination-worldwide, 2006. MMWR Morb Mortal Wkly Rep 2008, 57(46):1249-1252.
9. del Canho R., Grosheide P.M., Schalm S.W., et al. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol 1994, 20(4):483-486.
10. Wiseman E., Fraser M.A., Holden S., et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009, 190:489-492.
11. Ngui S.L., O'Connell S., Eglin R.P., et al. Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J Infect Dis 1997, 176(5):1360-1365.
12. Lee S.D., Lo K.J., Tsai Y.T., et al. Maternal hepatitis B virus DNA in mother infant transmission. Lancet 1989, 1(8640):719.
13. Karthigesu V.D., Allison L.M., Ferguson M., et al. A hepatitis B virus variant found in the sera of immunised children induces a conformational change in the HBsAg " a" determinant. J Med Virol 1999, 58(4):346-352.
14. US Food and Drug Administration Code of federal regulations Title 21. Volume 4, Part 201-Labeling. Revised April 2009. Available at:, Accessed November 28, 2009. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm%3Ffr%3D201.57.
15. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
16. Lok A.S., McMahon B.J. Practice Guideline Committee, American Association for the Study of Liver Disease, AASLD Practice Guidelines Chronic Hepatitis B: Update 2009. Hepatology 2009, 50(3):661-662.
17. Keeffe E.B., Dieterich D.T., Han S.B., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6(12):1315-1341. [quiz: 1286].
18. Fontana R.J. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009, 49(Suppl 5):S185-S195.
19. U.S.Preventive Services Task Force Screening for hepatitis B virus infection in pregnancy: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009, 150(12):869-873. W154.
20. Weinbaum C.M., Williams I., Mast E.E., et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008, 57:1-20.
21. ACOG Committee on Practice Bulletins-Gynecology ACOG Practice Bulletin No. 86: viral hepatitis in pregnancy. Obstet Gynecol 2007, 110:941-955.
22. Ornoy A., Tenebaum A. Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio, and encephalitis virus. Reprod Toxicol 2006, 21:446-457.
23. Liaw Y.F., Leung N., Kao J.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
24. Xu D., Yan Y., Choi B.C., et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002, 67(1):20-26.
25. Lin H.H., Lee T.Y., Chen D.S., et al. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr 1987, 111:877-881.
26. Burk R.D., Hwang L.Y., Ho G.Y., et al. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994, 170:1418-1423.
27. Pande C., Kumar A., Patra S., et al. High maternal hepatitis virus DNA levels but not HBeAg positivity predicts perinatal transmission of hepatitis B to the newborn. Gastroenterology 2008, 134:A-760.
28. Su G., Pan K., Zhao N., et al. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004, 10(6):910-912.
29. Tang J.R., Hsu H.Y., Lin H.H., et al. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr 1998, 133(3):374-377.
30. del Canho R., Grosheide P.M., Mazel J.A., et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997, 15(15):1624-1630.
31. Ip H.M., Lelie P.N., Wong V.C., et al. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989, 1(8635):406-410.
32. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331(18):1173-1180.
33. Antiretroviral Pregnancy Registry Steering Committee Antiretroviral pregnancy registry international interim report for 1 January 1989 through 31 January 2009 2009, Registry Coordinating Center, Wilmington (NC), Available at:, Accessed November 26, 2009. http://www.APRegistry.com.
34. Dybul M., Fauci A.S., Bartlett J.G., et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations on the Panel on Clinical Practices for the Treatment of HIV. MMWR Recomm Rep 2002, 51:1-55.
35. Bridges E.G., Selden J.R., Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother 2008, 52(7):2521-2528.
36. Peters M.G. Special populations with hepatitis B virus infection. Hepatology 2009, 49(5 Suppl):S146.
37. Lok A.S., Fleischer R., Liang T.J., et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45(4):1056-1075.
38. Tyrell D.J.L., Mitchell M.C., De Man R.A., et al. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 1993, 18:112. (A).
39. Mirochnick M., Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004, 43(15):1071-1087.
40. Johnson M.A., Moore K.H., Yuen G.J., et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999, 36(1):41-66.
41. van Zonneveld M., van Nunen A.B., Niesters H.G., et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003, 10(4):294-297.
42. Xu W.M., Cui Y.T., Wang L., et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009, 16(2):94-103.
43. Chotiyaputta W., Lok A.S. Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection. J Viral Hepat 2009, 16:91-93. [editorial].
44. Dienstag J.L., Schiff E.R., Wright T.L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341(17):1256-1263.
45. ter Borg M.J., Leemans W.F., de Man R.A., et al. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008, 15(1):37-41.
46. Tran T. Management of hepatitis B in pregnancy: weighing the options. Cleve Clin J Med 2009, 76(Suppl 3):S25-S29.
47. Fwu C.-W., Chien Y.-C., Kirk G.D., et al. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst 2009, 101:1019-1072.
48. Mast E.E., Margolis H.S., Fiore, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54:1-31.